NGL FINECHEM
Back to Balance Sheet
|
NGL FINECHEM Last 5 Year Contingent Liabilities History
[Consolidated]
| Mar2025 | Mar2024 | Mar2023 | Mar2022 | Mar2021 | |
|---|---|---|---|---|---|
| Contingent Liabilities | ₹0.62 Cr | ₹0.44 Cr | ₹0.10 Cr | ₹0.28 Cr | ₹0.28 Cr |
What is the latest Contingent Liabilities ratio of NGL FINECHEM ?
| Year | Contingent Liabilities |
|---|---|
| Mar2025 | ₹0.62 Cr |
| Mar2024 | ₹0.44 Cr |
| Mar2023 | ₹0.10 Cr |
| Mar2022 | ₹0.28 Cr |
| Mar2021 | ₹0.28 Cr |
How is Contingent Liabilities of NGL FINECHEM Trending?
| Years | Contingent Liabilities | % Change | |
|---|---|---|---|
| Mar2025 | ₹0.62 Cr | 40.59 | |
| Mar2024 | ₹0.44 Cr | 336.63 | |
| Mar2023 | ₹0.10 Cr | -63.67 | |
| Mar2022 | ₹0.28 Cr | 0.00 | |
| Mar2021 | ₹0.28 Cr | - | |
Compare Contingent Liabilities of peers of NGL FINECHEM
| Peers & Returns | Market Capitalization | 1 Week | 1 Month | 1 Year | ||
| NGL FINECHEM | ₹1,460.3 Cr | 1.5% | 8.1% | 125% | Stock Analytics | |
| SUN PHARMACEUTICAL INDUSTRIES | ₹434,999.0 Cr | 3.6% | 7% | 15.3% | Stock Analytics | |
| DIVIS LABORATORIES | ₹169,139.0 Cr | 1.1% | 5.8% | 14.8% | Stock Analytics | |
| TORRENT PHARMACEUTICALS | ₹149,791.0 Cr | 1.9% | 12.3% | 49.2% | Stock Analytics | |
| DR REDDYS LABORATORIES | ₹109,664.0 Cr | 1.8% | 5.9% | 14.8% | Stock Analytics | |
| CIPLA | ₹107,685.0 Cr | 1.6% | 0.2% | -5.4% | Stock Analytics | |
NGL FINECHEM Share Price vs Sensex
| Share Price Returns(%) | 1 Week | 1 Month | 1 Year |
| NGL FINECHEM | 1.5% |
8.1% |
125% |
| SENSEX | -2.5% |
-6.1% |
7% |
You may also like the below Video Courses